ATE348608T1 - Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne - Google Patents

Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne

Info

Publication number
ATE348608T1
ATE348608T1 AT04075431T AT04075431T ATE348608T1 AT E348608 T1 ATE348608 T1 AT E348608T1 AT 04075431 T AT04075431 T AT 04075431T AT 04075431 T AT04075431 T AT 04075431T AT E348608 T1 ATE348608 T1 AT E348608T1
Authority
AT
Austria
Prior art keywords
migraines
hiv
colon cancer
receptor ligand
use against
Prior art date
Application number
AT04075431T
Other languages
English (en)
Inventor
Mark Bamford
Richard Howard Green
Richard Coles
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918745.2A external-priority patent/GB9918745D0/en
Priority claimed from GBGB9928437.4A external-priority patent/GB9928437D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE348608T1 publication Critical patent/ATE348608T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04075431T 1999-08-10 2000-08-08 Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne ATE348608T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918745.2A GB9918745D0 (en) 1999-08-10 1999-08-10 Medical uses
GBGB9928437.4A GB9928437D0 (en) 1999-12-01 1999-12-01 Medical uses

Publications (1)

Publication Number Publication Date
ATE348608T1 true ATE348608T1 (de) 2007-01-15

Family

ID=26315833

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00956408T ATE272398T1 (de) 1999-08-10 2000-08-08 Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
AT04075431T ATE348608T1 (de) 1999-08-10 2000-08-08 Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00956408T ATE272398T1 (de) 1999-08-10 2000-08-08 Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz

Country Status (8)

Country Link
US (1) US6861441B1 (de)
EP (2) EP1442744B1 (de)
JP (1) JP2003506404A (de)
AT (2) ATE272398T1 (de)
AU (1) AU6836200A (de)
DE (2) DE60032524T2 (de)
ES (2) ES2274378T3 (de)
WO (1) WO2001010426A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AU2000234451B2 (en) * 2000-03-24 2005-09-29 Asterand Uk Acquisition Limited Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0031295D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) * 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
ATE371454T1 (de) * 2001-10-31 2007-09-15 Medical Res Council Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
HUE029417T2 (en) 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
JP2007533723A (ja) * 2004-04-20 2007-11-22 ファイザー・プロダクツ・インク α２δリガンドを含む組合せ
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
GB0602900D0 (en) * 2006-02-13 2006-03-22 Glaxo Group Ltd Novel Compounds
GB0615111D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel compounds
GB0616498D0 (en) * 2006-08-18 2006-09-27 Glaxo Group Ltd Novel compounds
GB0620619D0 (en) * 2006-10-17 2006-11-29 Glaxo Group Ltd Novel compounds
GB0623203D0 (en) * 2006-11-21 2007-01-03 Glaxo Group Ltd Novel compounds
CN101686985A (zh) 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
GB0715463D0 (en) * 2007-08-08 2007-09-19 Glaxo Group Ltd Novel compounds
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CA2754702C (en) * 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
EP2507267B1 (de) * 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Zusammensetzungen und verfahren zur erhöhung der serumshaltbarkeit von fc-fusionsproteinen
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
WO2013167582A1 (en) 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
TWI664969B (zh) * 2014-03-06 2019-07-11 雅瑞塔那醫療公司 格拉匹綸(ｇｒａｐｉｐｒａｎｔ)組合物及其使用方法
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH574409A5 (en) * 1972-09-29 1976-04-15 Sandoz Ag Benzo(f)isoindoline derivs - with antidepressant and analgesic activity
IL62734A (en) * 1980-04-30 1985-10-31 Glaxo Group Ltd Aminocyclopentane alkenoic acids and esters,their preparation and pharmaceutical formulations
US4618683A (en) * 1982-06-01 1986-10-21 Abbott Laboratories Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives
NO872963L (no) * 1986-07-29 1988-02-01 Glaxo Group Ltd Isokinolinderivater.
EP0501579A1 (de) 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalinlactone als Inhibitoren der Leukotrien-Biosynthese
EP0520573A1 (de) * 1991-06-27 1992-12-30 Glaxo Inc. Derivate von cyclischen Imiden
ATE224377T1 (de) 1994-04-29 2002-10-15 Takeda Chemical Industries Ltd Kondensierte heterocyclische verbindung, deren herstellung und verwendung als gnrh antagonisten
AU4467396A (en) * 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors

Also Published As

Publication number Publication date
DE60032524T2 (de) 2007-07-05
JP2003506404A (ja) 2003-02-18
EP1442744A3 (de) 2005-04-06
DE60032524D1 (de) 2007-02-01
WO2001010426A2 (en) 2001-02-15
ATE272398T1 (de) 2004-08-15
US6861441B1 (en) 2005-03-01
ES2274378T3 (es) 2007-05-16
AU6836200A (en) 2001-03-05
WO2001010426A3 (en) 2001-12-20
EP1442744B1 (de) 2006-12-20
EP1202730B1 (de) 2004-08-04
DE60012751D1 (de) 2004-09-09
DE60012751T2 (de) 2005-01-20
EP1442744A2 (de) 2004-08-04
ES2225199T3 (es) 2005-03-16
EP1202730A2 (de) 2002-05-08

Similar Documents

Publication Publication Date Title
DE60032524D1 (de) EP4 Rezeptor Ligand und Verwendung gegen neuropatischen Schmerzen, Colon Krebs, HIV und Migräne
DE60119397D1 (de) "2-Oxo-1-Pyrrolidinderivate und ihre pharmazeutische Verwendung"
ATE448226T1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
ATE350036T1 (de) Tetrahydroquinolin-derivate
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
HK1041256A1 (zh) 靛系双吲衍生物
ATE180468T1 (de) Anthranilsäure derivate
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
ATE278661T1 (de) Anthranilsäurederivate
PL377467A1 (pl) Aromatyczne związki jako środki przeciwzapalne, immunomodulujące i antyproliferacyjne
ATE295841T1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
ATE228518T1 (de) Amid derivate
DE60013994D1 (de) 1,2-Disubstituierte 1,4-Dihydro-4-oxochinolin-Verbindungen
DE69810960D1 (de) 2-phenoxyanilin-derivate
DE60043497D1 (de) 4-Substituierte-3,6-Anhydro-Galaktosederivate und ihre pharmazeutische Verwendung
ES2102772T3 (es) Compuesto citotoxico y antiviral.
DE69814563D1 (de) Pyrrolo-(3,2-b)pyridine und ihre Verwendung als 5-HT1F Agonisten
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
DE60210283D1 (de) 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
ATE252546T1 (de) 3-(3-hydroxyphenyl)-3-amino-propionamidderivate
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties